Member Info for TrickyEFC

Have a look at LTS Lohmann previous hits.

They had some good form.

https://www.ltslohmann.com/en/press-releases/lts-and-awakn-life-sciences-enter-into-global-licensing-agreement/

Glad they all highly confident of the k-now how

Patents and related knowledge as an intangible asset (note 10)

The estimates and assumptions in relation to the carrying value of the know-how intangible assets are considered to have the most significant effect on the carrying amounts of the financial statements.

Management have prepared a 5 year financial forecast ending at December 2028 which looks at the revenue generating ability of these intangible assets. They have confidence in various networks and contracts that the know-how will allow the Group to generate royalty and licensing revenue with relatively low associated costs. The Directors have a high level of confidence that these contracts will ultimately prove to be highly lucrative for the Group and support the current carrying value of the intangible assets.

Positives.

Valuation & impairment

· Audit evidence obtained did not suggest any significant issues with the project plan which would lead to increased doubt over the eventual success of the project

· There is substantial headroom in the sales modelling with respect to this contract, should the ultimate commercial success of the project be less than anticipated

· The contract in place is not exclusive, therefore there will be other potential revenue generating partnerships that the company can enter into

The Group seeks to manage liquidity risk by regularly reviewing cash flow budgets and forecasts to ensure that sufficient liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably. The Group deems there is sufficient liquidity for the foreseeable future.

Should have about enough cash for another 2/3 months.

As it stands. Get the raise done at 0.10p or above and 3 mill should see us good for 18months plus.

The Group had cash and cash equivalents at period end as below:

31 Dec 2024 £'000

31 Dec 2023 £'000

Cash and cash equivalents

757

155

757

155

Never said £10k was big but looking back on the day was the biggest trade of the day.

also noticed action was weighted 2 to 1 for the buyers today.

Last day before long weekend here's to a good one

Since launch and raising 1.8 million last July.

December

Study Highlights:

· Social Interaction and Information Transfer: AW21003 enhanced observer animals' ability to learn and retain information, as evidenced by increased consumption of a demonstrated (correct) flavoured diet versus a novel (incorrect) one.

· Behavioural Safety Indicators: Unlike MDMA, a comparative test standard known to induce stereotyped behaviours (e.g., flat body posture and lateral head weaving), AW21003-treated animals exhibited no such behaviours, suggesting a favourable safety profile.

· Unique Observations: Test-standard animals preferred the correct diet, indicating baseline pro-social tendencies in the experimental design. AW21003-treated animals displayed complex preferences requiring further investigation.

The study was led by Dr. Madeline King, Assistant Professor in the School of Life Sciences, Faculty of Medicine & Health Sciences at the University of Nottingham.

January

Shares in Solvonis Therapeutics PLC rose 15% after the company confirmed that the US Food and Drug Administration (FDA) supports AWKN-002 progression directly to phase IIb clinical trials without additional data.

AWKN-002, an oral thin film of esketamine combined with structured alcohol education, is being developed to treat alcohol use disorder.

The FDA also approved the use of the 505(b)(2) pathway, allowing existing data from other esketamine products to streamline development and accelerate market

March

In-vitro screening for SERT, DAT, and NET release - Evotec appointed by Awakn to lead key preclinical testing.

To ensure the highest standard of preclinical validation, Awakn has appointed Evotec, a globally recognised leader in drug discovery and development, to conduct in-vitro screening for SERT, DAT, and NET release activity.

Evotec brings world-class expertise in:

· Neurotransmitter pharmacology

· High-throughput screening

· Precision drug discovery

Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.

This in-vitro testing phase, which builds on the positive animal testing results, is expected to be completed by the end of July 2025, aligning with the revised Programme timeline.

March

Positive progress on European Patent Application for the AWKN-SDN-14 programme

Also so far and not to jinx it long term large holders ain't sold a bean since taking positions last year.

So anything less than 0.10p would be a sort term kick to the balls. Market needs to start playing ball here. Hopefully once funding is done it will be the much overdue catalyst to get this into fair value region of 0.45 to 0.6p range.

£9-12 million value. Surely am not the only one who thinks this is undervalued.

Initial fundraise after launch last July I believe was .10p

I would expect the coming one to be above this amount as the progress of the company over the last 9 months has only been positive progression.

Posted this other day. * Now £2.98m 😂

They looking to get authority to issue up to 7.5b shares. This will provide funding for the new enlarged company for at least 12 months and will also allow ample space to issue warrants if they end up being executed.

SVNS currently have 2.3b shares in issue valued at *£3.73million

awakn take over for consideration of 2.01b shares.

based on current price of 0.1625 values company at £7.1million.

Now dare I say the exciting part, the fund raise. SVNS are looking to have authority to issue up to 7.5b shares.

So if we remove the current shares and the consideration shares that leaves room for 3,125,621,408 shares for equity.

3.12b x 0.075p £2.3million

x 0.10p = £3.125 million

x0.15p = ££4.6million

x0.20p = £6.2 million

Not yet awaiting for fundraise

A 1.3m buy order went through at 4pm.

Hopefully a proper blue day tomorrow

A small screen don't make it any easier.

Operating loss was reduced.

But long RNs

His comments accompanied the release of 2024 results, which revealed the group narrowed its operating loss to £1.38 from £3.12 million a year earlier.

Https://www.proactiveinvestors.co.uk/companies/news/1069794/solvonis-therapeutics-eyes-completion-of-awakn-acquisition-following-transformative-2024.html

Major anyone paying attention today would understand dealers post crystal clear.

My last post spells it out though for anyone who didn't have 👀 on this today

Dealer it's comical. That one day ramp and dump poster. Buying in at 11am and then ramping the bejesus out of it.

Pure scum.

Hope no one was silly enough to give it credence. Although some posters here today did actually converse with him.

Ps poster has gone. Ya don't even need to report em now caus ya now they will be gone anyways.

Also that second day running more buys than sells.

Complete Mickey take here.

25 16:19:14 0.795 754,215 Buy* 5,996

Last buy yesterday same as today.

Fu CK the mm and the UT

Ramp a dump bepe

Bepe if ya chill out me may have more trades than posts 💪

No 🎣 gl

M.O Ramp a dump